Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
Context Therapeutics Inc. (CNTX)
Company Research
Source: GlobeNewswire
CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers Company expects to enroll first patient in mid-2024 PHILADELPHIA, May 02, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared its Investigational New Drug (“IND”) application for CTIM-76, a Claudin 6 (“CLDN6”) x CD3 T cell engaging bispecific antibody. The IND supports the initiation of a Phase 1 dose escalation and expansion clinical trial of CTIM-76 in patients with CLDN6-positive gynecologic and testicular cancers. The Company anticipates the enrollment of the first patient in the dose escalation portion of its clinical trial in mid-2024. “The FDA’s clearance of our IND marks an important achievement for Context, allowing us to proceed with the Phase 1 clinical program for this potentially best-in-cl
Show less
Read more
Impact Snapshot
Event Time:
CNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNTX alerts
High impacting Context Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
CNTX
News
- Context Therapeutics Inc. (NASDAQ: CNTX) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $4.50 price target on the stock.MarketBeat
- Context Therapeutics Inc. (NASDAQ: CNTX) is now covered by analysts at Piper Sandler Companies. They set an "overweight" rating and a $4.50 price target on the stock.MarketBeat
- Context Therapeutics Inc. (CNTX) Upgraded to Buy: Here's Why [Yahoo! Finance]Yahoo! Finance
- Context Therapeutics Inc. (NASDAQ: CNTX) had its price target raised by analysts at HC Wainwright from $4.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- Context Therapeutics Inc. (NASDAQ: CNTX) had its price target raised by analysts at Maxim Group from $4.00 to $10.00. They now have a "buy" rating on the stock.MarketBeat
CNTX
Analyst Actions
- 5/9/24 - Maxim Group
CNTX
Sec Filings
- 5/16/24 - Form D
- 5/13/24 - Form SC
- 5/10/24 - Form SC
- CNTX's page on the SEC website